Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Rating of “Hold” by Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been given an average rating of “Hold” by the five brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $4.00.

Several brokerages recently commented on MCRB. The Goldman Sachs Group cut their price target on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. Chardan Capital restated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research report on Thursday, March 20th. Finally, StockNews.com lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, April 10th.

Hedge Funds Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of MCRB. Charles Schwab Investment Management Inc. lifted its stake in Seres Therapeutics by 42.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares in the last quarter. FMR LLC lifted its position in Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares in the last quarter. State Street Corp boosted its stake in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares during the last quarter. Geode Capital Management LLC grew its holdings in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. Finally, Virtu Financial LLC increased its stake in shares of Seres Therapeutics by 44.8% in the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Trading Up 12.3 %

NASDAQ MCRB opened at $0.66 on Tuesday. The stock has a market capitalization of $115.65 million, a price-to-earnings ratio of -2.88 and a beta of 2.54. The stock has a 50-day moving average of $0.72 and a 200 day moving average of $0.79. Seres Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.53.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.